Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
World Journal of Surgery
Erschienen in: World Journal of Surgery 7/2017

03.03.2017 | Surgical Symposium Contribution

From Heartburn to Barrett’s Esophagus, and Beyond

verfasst von: Francisco Schlottmann, Marco G. Patti, Nicholas J. Shaheen

Erschienen in: World Journal of Surgery | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Gastroesophageal reflux disease (GERD) affects an estimated 20% of the population in the USA, and its prevalence is increasing worldwide. About 10–15% of patients with GERD will develop Barrett’s esophagus (BE).

Aims

The aims of this study were to review the available evidence of the pathophysiology of BE and the role of anti-reflux surgery in the treatment of this disease.

Results

The transformation of the squamous epithelium into columnar epithelium with goblet cells is due to the chronic injury produced by repeated reflux episodes. It involves genetic mutations that in some patients may lead to high-grade dysplasia and cancer. There is no strong evidence that anti-reflux surgery is associated with resolution or improvement in BE, and its indications should be the same as for other GERD patients without BE.

Conclusions

Patients with BE without dysplasia require endoscopic surveillance, while those with low- or high-grade dysplasia should have consideration of endoscopic eradication therapy followed by surveillance. New endoscopic treatment modalities are being developed, which hold the promise to improve the management of patients with BE.
Literatur
1.
El-Serag HN, Sweet S, Winchester CC et al (2014) Update on the epidemiology of gastro-esophageal reflux disease: a systematic review. Gut 63:871–880CrossRefPubMed
2.
Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R (2002) The burden of selected digestive diseases in the United States. Gastroenterology 122:1500–1511CrossRefPubMed
3.
Pohl H, Welch HG (2005) The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142–146CrossRefPubMed
4.
5.
Shaheen NJ, Falk GW, Iyer PG, Gerson LB (2016) ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 111:30–50CrossRefPubMed
6.
Bhat S, Coleman HG, Yousef F et al (2011) Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst 103:1049–1057CrossRefPubMedPubMedCentral
7.
Bandla S, Peters JH, Ruff D et al (2014) Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells. Ann Surg 260:72–80CrossRefPubMedPubMedCentral
8.
Zagari RM, Fuccio L, Wallander MA et al (2008) Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano–Monghidoro study. Gut 57:1354–1359CrossRefPubMed
9.
Ronkainen J, Aro P, Storskrubb T et al (2005) Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology 129:1825–1831CrossRefPubMed
10.
van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ (2005) Increasing incidence of Barrett’s esophagus in the general population. Gut 54:1062–1066CrossRefPubMedPubMedCentral
11.
Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA (1990) Prevalence of columnar lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 99:918–922CrossRefPubMed
12.
Johansson J, Hakansson HO, Mellblom L et al (2005) Prevalence of precancerous and other metaplasia in the distal oesophagus and gastro-oesophageal junction. Scand J Gastroenterol 40:893–902CrossRefPubMed
13.
Lieberman DA (1997) Risk factors for Barrett’s esophagus in community-based practice. Am J Gastroenterol 92:1293–1297PubMed
14.
Oberg S, Johansson J, Wenner J, Walther B (2002) Metaplastic columnar mucosa in the cervical esophagus after esophagectomy. Ann Surg 235:338–345CrossRefPubMedPubMedCentral
15.
O’Riordan JM, Tucker ON, Byrne PJ, McDonald GS, Ravi N, Keeling PW, Reynolds JV (2004) Factors influencing the development of Barrett’s epithelium in the esophageal remnant post-esophagectomy. Am J Gastroenterol 99:205–211CrossRefPubMed
16.
Tobey NA, Hosseini SS, Argote CM, Dobrucali AM, Awayda MS, Orlando RC (2004) Dilated intercellular spaces and shunt permeability in non-erosive acid-damaged esophageal epithelium. Am J Gastroenterol 99:13–22CrossRefPubMed
17.
Tobey NA, Orlando RC (1991) Mechanisms of acid injury to rabbit esophageal epithelium. Role of basolateral cell membrane acidification. Gastroenterology 101:1220–1228CrossRefPubMed
18.
Souza RF, Krishnan K, Spechler SJ (2008) Acid, bile, and CDX: the ABCs of making Barrett’s metaplasia. Am J Gastrointest Liver Physiol 295:211–218CrossRef
19.
Sarosi G, Brown G, Jaiswal K, Feagins LA, Lee E, Crook TW, Souza RF, Zou YS, Shay JW, Spechler SJ (2008) Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett’s esophagus. Dis Esophagus 21(1):43–50CrossRefPubMed
20.
Nakagawa H, Whelan K, Lynch JP (2015) Mechanisms of Barrett’s oesophagus: intestinal differentiation, stem cells, and tissue models. Best Pract Res Clin Gastroenterol 29(1):3–16CrossRefPubMed
21.
22.
Oberg S, Ritter MP, Crookes PF, Fein M, Mason RJ, Gadensytätter M, Brenner CG, Peters JH, DeMeester TR (1998) Gastroesophageal reflux disease and mucosal injury with emphasis on short-segment Barrett’s esophagus and duodenogastroesophageal reflux. J Gastrointest Surg 2:547–553CrossRefPubMed
23.
Fein M, Ireland AP, Ritter MP, Peters JH, Hagen JA, Bremner CG, DeMeester TR (1997) Duodenogastric reflux potentiates the injurious effects of gastroesophageal reflux. J Gastrointest Surg. 1:27–32CrossRefPubMed
24.
Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA (1995) Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 222:525–531CrossRefPubMedPubMedCentral
25.
Oberg S, Peters JH, DeMeester TR, Lord RV, Johansson J, DeMeester SR, Hagen JA (2000) Determinants of intestinal metaplasia within the columnar-lined esophagus. Arch Surg 135(6):651–655CrossRefPubMed
26.
Theisen J, Peters JH, Fein M, Hughes M, Hagen JA, Demeester SR, Demeester TR, Laird PW (2005) The mutagenic potential of duodenoesophageal reflux. Ann Surg 241:63–68PubMedPubMedCentral
27.
Kazumori H, Ishihara S, Rumi MA et al (2006) Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett’s epithelium. Gut 55:16–25CrossRefPubMedPubMedCentral
28.
Tamagawa Y, Ishimura N, Uno G, Aimi M, Oshima N, Yuki T, Sato S, Ishihara S, Kinoshita Y (2016) Bile acids induce Delta-like 1 expression via Cdx2-dependent pathway in the development of Barrett’s esophagus. Lab Invest 96(3):325–337CrossRefPubMed
29.
Reid BJ, Sanchez CA, Blount PL, Levine DS (1993) Barrett’s esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 105:119–129CrossRefPubMed
30.
Hvid-Jensen F, Pedersen L, Drewes AM et al (2011) Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 365:1375–1383CrossRefPubMed
31.
Dulai GS, Guha S, Kahn KL et al (2002) Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 122:26–33CrossRefPubMed
32.
Gopal DV, Lieberman DA, Magaret N et al (2003) Risk factors for dysplasia in patients with Barrett’s esophagus (BE): results from a multicenter consortium. Dig Dis Sci 48:1537–1541CrossRefPubMed
33.
Hampel H, Abraham NS, El-Serag HB (2005) Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143:199–211CrossRefPubMed
34.
Singh S, Sharma AN, Murad MH et al (2013) Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 11:1399–1412CrossRefPubMed
35.
Andrici J, Cox MR, Eslick GD (2013) Cigarette smoking and the risk of Barrett’s esophagus: a systematic review and meta-analysis. J Gastroenterol Hepatol 28:1258–1273CrossRefPubMed
36.
Singh S, Garg SK, Singh PP et al (2014) Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut 63:1229–1237CrossRefPubMed
37.
Zhang S, Zhang XQ, Ding XW et al (2014) Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a meta-analysis. Br J Cancer 110:2378–2388CrossRefPubMedPubMedCentral
38.
Singh S, Singh AG, Singh PP et al (2013) Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 11:620–629CrossRefPubMedPubMedCentral
39.
Desai TK, Krishnan K, Samala N et al (2012) The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut 61:970–976CrossRefPubMed
40.
Singh S, Manickam P, Amin AV et al (2014) Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc 79:897–909CrossRefPubMed
41.
Rastogi A, Puli S, El-Serag HB et al (2008) Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 67:394–398CrossRefPubMed
42.
Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM (1999) Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc 50:23–26CrossRefPubMed
43.
Montgomery E, Bronner MP, Goldblum JR et al (2001) Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 32:368–378CrossRefPubMed
44.
Curvers WL, ten Kate FJ, Krishnadath KK et al (2010) Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol 105:1523–1530CrossRefPubMed
45.
Wani S, Falk GW, Post J et al (2011) Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology 141:1179–1186CrossRefPubMed
46.
Phoa KN, van Vilsteren FG, Weusten BL et al (2014) Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 311:1209–1217CrossRefPubMed
47.
Katz PO, Zavala S (2010) Proton pump inhibitors in the management of GERD. J Gastrointest Surg 14:62–66CrossRef
48.
Tamhankar AP, Peters JH, Portale G, Hsieh CC, Hagen JA, Bremner CG, DeMeester TR (2004) Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg 8(7):890–897CrossRefPubMed
49.
Blonski W, Vela MF, Castell DO (2009) Comparison of reflux frequency during prolonged multichannel intraluminal impedance and pH monitoring on and off acid suppression therapy. J Clin Gastroenterol 43(9):816–820CrossRefPubMed
50.
Rickenbacher N, Kötter T, Kochen MM, Scherer M, Blozik E (2014) Fundoplication versus medical management of gastroesophageal reflux disease: systematic review and meta-analysis. Surg Endosc 28(1):143–155CrossRefPubMed
51.
Faria R, Bojke L, Epstein D, Corbacho B, Sculpher M, REFLUX trial group (2013) Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial. Br J Surg 100(9):1205–1213CrossRefPubMed
52.
Oelschlager BK, Barreca M, Chang L, Oleynikov D, Pellegrini CA (2003) Clinical and pathologic response of Barrett’s esophagus to laparoscopic antireflux surgery. Ann Surg 238(4):458–464PubMedPubMedCentral
53.
Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D (1998) The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett’s esophagus. Am J Gastroenterol 93(4):536–541CrossRefPubMed
54.
Oberg S, Wenner J, Johansson J, Walther B, Willén R (2005) Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 242(1):49–54CrossRefPubMedPubMedCentral
55.
Chang EY, Morris CD, Seltman AK, O’Rourke RW, Chan BK, Hunter JG, Jobe BA (2007) The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review. Ann Surg 246(1):11–21CrossRefPubMedPubMedCentral
56.
Parrilla P, Martínez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J, Canteras M (2003) Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg 237(3):291–298PubMedPubMedCentral
57.
Lagergren J, Ye W, Lagergren P, Lu Y (2010) The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology 138(4):1297–1301CrossRefPubMed
58.
Qumseya BJ, Wang H, Badie N, Uzomba RN, Parasa S, White DL, Wolfsen H, Sharma P, Wallace MB (2013) Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett’s esophagus: a meta-analysis and systematic review. Clin Gastroenterol Hepatol 11(12):1562–1570CrossRefPubMedPubMedCentral
59.
Canto MI, Anandasabapathy S, Brugge W, Falk GW, Dunbar KB, Zhang Z, Woods K, Almario JA, Schell U, Goldblum J, Maitra A, Montgomery E, Kiesslich R, Confocal Endomicroscopy for Barrett’s Esophagus or Confocal Endomicroscopy for Barrett’s Esophagus (CEBE) Trial Group (2014) In vivo endomicroscopy improves detection of Barrett’s esophagus-related neoplasia: a multicenter international randomized controlled trial (with video). Gastrointest Endosc 79(2):211–221CrossRefPubMed
60.
Suter MJ, Gora MJ, Lauwers GY, Arnason T, Sauk J, Gallagher KA, Kava L, Tan KM, Soomro AR, Gallagher TP, Gardecki JA, Bouma BE, Rosenberg M, Nishioka NS, Tearney GJ (2014) Esophageal-guided biopsy with volumetric laser endomicroscopy and laser cautery marking: a pilot clinical study. Gastrointest Endosc 79(6):886–896CrossRefPubMed
61.
Vennalaganti PR, Naag Kanakadandi V, Gross SA, Parasa S, Wang KK, Gupta N, Sharma P (2015) Inter-observer agreement among pathologists using wide-area transepithelial sampling with computer-assisted analysis in patients with Barrett’s esophagus. Am J Gastroenterol 110(9):1257–1260CrossRefPubMed
62.
Kadri SR, Lao-Sirieix P, O’Donovan M, Debiram I, Das M, Blazeby JM, Emery J, Boussioutas A, Morris H, Walter FM, Pharoah P, Hardwick RH, Fitzgerald RC (2010) Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ 341:c4372CrossRefPubMedPubMedCentral
63.
Weaver JM, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, Murtaza M, Ong CA, Lao-Sirieix P, Dunning MJ, Smith L, Smith ML, Anderson CL, Carvalho B, O’Donovan M, Underwood TJ, May AP, Grehan N, Hardwick R, Davies J, Oloumi A, Aparicio S, Caldas C, Eldridge MD, Edwards PA, Rosenfeld N, Tavaré S, Fitzgerald RC, OCCAMS Consortium (2014) Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 46(8):837–843CrossRefPubMedPubMedCentral
64.
Kastelein F, Biermann K, Steyerberg EW, Verheij J, Kalisvaart M, Looijenga LH, Stoop HA, Walter L, Kuipers EJ, Spaander MC, Bruno MJ, ProBar-study group (2013) Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus. Gut 62(12):1676–1683CrossRefPubMed
65.
Cabibi D, Caruso S, Bazan V, Castiglia M, Bronte G, Ingrao S, Fanale D, Cangemi A, Calò V, Listì A, Incorvaia L, Galvano A, Pantuso G, Fiorentino E, Castorina S, Russo A (2016) Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. Oncotarget 7(30):47821–47830PubMedPubMedCentral
Metadaten
Titel
From Heartburn to Barrett’s Esophagus, and Beyond
verfasst von
Francisco Schlottmann
Marco G. Patti
Nicholas J. Shaheen
Publikationsdatum
03.03.2017
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 7/2017
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-017-3957-z

Weitere Artikel der Ausgabe 7/2017

World Journal of Surgery 7/2017 Zur Ausgabe

Erratum

Erratum to: Glasgow Prognostic Score and Prognosis After Hepatectomy for Hepatocellular Carcinoma

Original Scientific Report

Time to CT and Surgery for HPB Trauma in Scotland Prior to the Introduction of Major Trauma Centres

Surgical Symposium Contribution

Medical Treatment of Gastroesophageal Reflux Disease

Original Scientific Report

Validation of the Surgical Apgar Score After Laparotomy at a Tertiary Referral Hospital in Rwanda

Original Scientific Report

The Role of 18F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Predicting Pathologic Response After Induction Therapy for Thymic Epithelial Tumors

Original Scientific Report

Survey of Emergency and Essential Surgical, Obstetric and Anaesthetic Services Available in Bangladeshi Government Health Facilities

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.